FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| Enobosarm | Metastatic Breast Cancer | PHASE3 | TERMINATED |
| Enobosarm & Abemaciclib Combo | Metastatic Breast Cancer | PHASE3 | TERMINATED |
| Enzalutamide, Abiraterone | Metastatic Castration-resistant Prostate Cancer | PHASE3 | TERMINATED |
| Exemestane | Metastatic Breast Cancer | PHASE3 | TERMINATED |
| non-steroidal AI, or steroidal AI (exeme | Metastatic Breast Cancer | PHASE3 | TERMINATED |
| Exemestane monotherapy, exemestane plus | Metastatic Breast Cancer | PHASE2 | WITHDRAWN |
| Sabizabulin | Metastatic Breast Cancer | PHASE2 | WITHDRAWN |
| Sabizabulin/Sacituzumab govitecan-hziy C | Metastatic Triple Negative Breast Cancer | PHASE2 | WITHDRAWN |
| Sacituzumab Govitecan-hziy | Metastatic Triple Negative Breast Cancer | PHASE2 | WITHDRAWN |
| Semaglutide | Muscle Loss | PHASE2 | COMPLETED |
VERU holds $27.6M in cash and burns about $7.5M/quarter from operations, giving an estimated runway of 11 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for VERU free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-05-06 | STEINER MITCHELL SHUSTER |
Purchase | $0 |
| 2026-05-06 | BARNETTE K GARY |
Purchase | $0 |
| 2026-05-06 | FISCH HARRY |
Purchase | $0 |
| 2026-05-06 | Hyun Grace |
Purchase | $0 |
| 2026-05-06 | Katzovitz Loren Mark |
Purchase | $0 |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for VERU and 2 more tickers of your choice.
Create Free Account →